EVEREST MED(01952),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01952 EVEREST MED

Trading 03-05 10:28:34

36.100

+2.020

+5.93%

High36.140	Low34.180	Vol1.41M
Open34.180	D1 Closing34.080	Amplitude5.75%
Mkt Cap12.78B	Tradable Cap12.78B	Total Shares354.00M
T/O49.69M	T/O Rate0.40%	Tradable Shares354.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"EVEREST MED","latestPrice":36.1,"timestamp":1772677698122,"preClose":34.08,"halted":0,"volume":1406000,"delay":0,"changeRate":0.05927230046948366,"floatShares":354000000,"shares":354000000,"eps":-3.18,"marketStatus":"Trading","change":2.02,"latestTime":"03-05 10:28:34","open":34.18,"high":36.14,"low":34.18,"amount":49689868,"amplitude":0.057512,"askPrice":36.1,"askSize":3500,"bidPrice":36.06,"bidSize":14000,"shortable":3,"etf":0,"ttmEps":-2.043,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1772683200000},"marketStatusCode":2,"adr":0,"listingDate":1602172800000,"exchange":"SEHK","adjPreClose":34.08,"openAndCloseTimeList":[[1772674200000,1772683200000],[1772686800000,1772697600000]],"volumeRatio":2.078891,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952","defaultTab":"news","newsList":[{"id":"1113601668","title":"EVEREST MED Achieves Favorable Outcome in Patent Protection for Nefecon®","url":"https://stock-news.laohu8.com/highlight/detail?id=1113601668","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113601668?lang=en_us&edition=fundamental","pubTime":"2026-02-27 15:32","pubTimestamp":1772177554,"startTime":"0","endTime":"0","summary":"On February 27, EVEREST MED (01952) announced a significant development in the patent protection of its innovative product, budesonide enteric-coated capsules (Nefecon®). The Guangzhou Intellectual...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","01952","BK1161"],"gpt_icon":0},{"id":"1121333319","title":"EVEREST MED Shareholders Pass Key Commercialization Agreements at Special Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1121333319","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121333319?lang=en_us&edition=fundamental","pubTime":"2026-02-24 18:08","pubTimestamp":1771927696,"startTime":"0","endTime":"0","summary":"EVEREST MED (01952) announced the successful conclusion of its Special General Meeting held virtually on February 24, 2026, where all proposed resolutions were formally approved by shareholders....","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1583","BK1161","BK1574"],"gpt_icon":0},{"id":"1164816346","title":"Everest Medicines (1952) Releases EGM Poll Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1164816346","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164816346?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:42","pubTimestamp":1771926134,"startTime":"0","endTime":"0","summary":"On 24 February 2026, Everest Medicines (1952) held its Extraordinary General Meeting in a virtual format. Four ordinary resolutions were voted on by poll, with all passing by a clear majority....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"gpt_icon":0},{"id":"2613879629","title":"Everest Medicines Ltd. Held Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2613879629","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613879629?lang=en_us&edition=fundamental","pubTime":"2026-02-24 17:03","pubTimestamp":1771923827,"startTime":"0","endTime":"0","summary":"Everest Medicines Ltd. held an extraordinary general meeting on Feb. 24, 2026. Shareholders approved the Commercialization Service Agreement and related transactions, approved a grant of awards to Mr. Yifang Wu under the Pre-IPO ESOP, approved and adopted the 2026 Share Scheme with a 10% scheme mandate limit, and approved and adopted a 0.5% service provider sublimit under the 2026 Share Scheme.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL43k2db:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","01952","BK1583"],"gpt_icon":0},{"id":"2611130118","title":"Everest Medicines (SEHK:1952) Valuation Check After Recent Share Price Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2611130118","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611130118?lang=en_us&edition=fundamental","pubTime":"2026-02-14 11:29","pubTimestamp":1771039772,"startTime":"0","endTime":"0","summary":"What is moving Everest Medicines after recent performance\nEverest Medicines (SEHK:1952) has caught investor attention after a recent 2.5% one-day return, which contrasts with a decline of about 17.8% over the past three months and a modest gain over the past year.\nSee our latest analysis for Everest Medicines.\nThat 2.5% one day share price gain comes after a 90 day share price return of about an 18% decline, while the 1 year total shareholder return of around 5% hints that shorter term...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-check-after-recent-shar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-check-after-recent-shar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1583","BK1574","01952","MDCO"],"gpt_icon":0},{"id":"1136423519","title":"Everest MED Shares Surge Afternoon on New Drug Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1136423519","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136423519?lang=en_us&edition=fundamental","pubTime":"2026-02-06 14:14","pubTimestamp":1770358462,"startTime":"0","endTime":"0","summary":"Everest MED (01952) saw its shares rise more than 5% in afternoon trading. At the time of writing, the stock was up 3.4%, trading at HK$40.18 with a turnover of HK$151 million. The increase follows...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","VT","01952","BK4585","BK4588","VXUS","BK1161"],"gpt_icon":0},{"id":"1199951087","title":"Everest Medicines (1952) Secures NMPA Approval for VELSIPITY® in China to Treat Moderately-to-Severely Active Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1199951087","media":"Bulletin Express","labels":["policyRegulatory","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199951087?lang=en_us&edition=fundamental","pubTime":"2026-02-06 12:23","pubTimestamp":1770351838,"startTime":"0","endTime":"0","summary":"Everest Medicines (1952) has obtained approval from China’s National Medical Products Administration for the New Drug Application of VELSIPITY® (etrasimod arginine tablets). The therapy is indicated...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"gpt_icon":0},{"id":"1162888296","title":"EVEREST MED Receives Chinese Approval for VELSIPITY® to Treat Moderate to Severe Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1162888296","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162888296?lang=en_us&edition=fundamental","pubTime":"2026-02-06 12:12","pubTimestamp":1770351155,"startTime":"0","endTime":"0","summary":"EVEREST MED announced that China's National Medical Products Administration has approved the New Drug Application for VELSIPITY® (argenine etrasimod tablets) for the treatment of adult patients with...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1161","BK1574","BK1583"],"gpt_icon":0},{"id":"2609558546","title":"Everest Medicines - Nmpa China Approves Drug Application for Velsipity for Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2609558546","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609558546?lang=en_us&edition=fundamental","pubTime":"2026-02-06 12:01","pubTimestamp":1770350472,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nFWN3Z11W5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01952","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2609558573","title":"China Approves Everest Medicines' VELSIPITY for Moderately-to-Severely Active Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2609558573","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609558573?lang=en_us&edition=fundamental","pubTime":"2026-02-06 12:01","pubTimestamp":1770350469,"startTime":"0","endTime":"0","summary":"Everest Medicines Limited announced that the National Medical Products Administration  of China has approved the New Drug Application  for VELSIPITY  for the treatment of moderately to severely active ulcerative colitis in adults. The approval covers patients who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. This regulatory approval marks a significant step in the company's strategy to expand its autoimmune portfolio and commercial product offerings in China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Ex","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL1YkwtY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"1173157585","title":"Everest Medicines (01952) Publishes January 2026 Monthly Return on Equity Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1173157585","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173157585?lang=en_us&edition=fundamental","pubTime":"2026-02-05 16:50","pubTimestamp":1770281424,"startTime":"0","endTime":"0","summary":"Everest Medicines Limited (stock code: 01952) disclosed its latest monthly return, covering movements in securities for January 2026. The company’s authorized share capital stood at 500,000,000...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"gpt_icon":0},{"id":"2609343490","title":"Everest Medicines Acquires License to Commercialize Kidney Drug MT1013","url":"https://stock-news.laohu8.com/highlight/detail?id=2609343490","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609343490?lang=en_us&edition=fundamental","pubTime":"2026-02-05 09:55","pubTimestamp":1770256547,"startTime":"0","endTime":"0","summary":"Everest Medicines (HKG:1952) acquired a license to MT1013 from Shaanxi Micot Pharmaceutical Technology to commercialize the drug, according to a Hong Kong bourse filing Thursday.The firm will pay 200 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01952","BK1574","BK1583","MDCO","BK1161"],"gpt_icon":0},{"id":"2609484983","title":"BRIEF-Everest Medicines Inks Agreement With Micot To Commercialize MT1013","url":"https://stock-news.laohu8.com/highlight/detail?id=2609484983","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609484983?lang=en_us&edition=fundamental","pubTime":"2026-02-05 09:29","pubTimestamp":1770254995,"startTime":"0","endTime":"0","summary":"BRIEF-Everest Medicines Inks Agreement With Micot To Commercialize MT1013Feb 5  - Everest Medicines Ltd 1952.HK:AGREEMENT WITH MICOT TO COMMERCIALIZE MT1013 IN GREATER CHINA AND OTHER ASIAN MARKETSUNIT'S PAYMENT OBLIGATIONS INCLUDE AN UPFRONT PAYMENT OF RMB200 MLN, OTHERSFurther company coverage: 1952.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nFWN3Z015K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"1140351616","title":"EVEREST MED (01952) Strengthens Renal Portfolio with Global First-in-Class Dual-Target Peptide Drug MT1013","url":"https://stock-news.laohu8.com/highlight/detail?id=1140351616","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140351616?lang=en_us&edition=fundamental","pubTime":"2026-02-05 07:50","pubTimestamp":1770249043,"startTime":"0","endTime":"0","summary":"On February 5th, the Hong Kong-listed innovative pharmaceutical company EVEREST MED (01952) announced it has entered into an exclusive commercialization licensing agreement with MicuRx...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"1115201232","title":"EVEREST MED Subsidiary Inks Deal with Micot for Commercialization of MT1013 Across Greater China and Asian Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=1115201232","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115201232?lang=en_us&edition=fundamental","pubTime":"2026-02-05 07:32","pubTimestamp":1770247949,"startTime":"0","endTime":"0","summary":"EVEREST MED (01952) announced that on February 4, 2026, its indirect wholly-owned subsidiary, Everest Medicines Technology Co., Ltd., entered into an agreement with Shaanxi Micot Pharmaceutical...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK1583","BK1161","BK1574","91218"],"gpt_icon":0},{"id":"2609131177","title":"Everest Medicines Ltd - Unit's Payment Obligations Include an Upfront Payment of RMB200 Mln, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2609131177","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609131177?lang=en_us&edition=fundamental","pubTime":"2026-02-05 07:01","pubTimestamp":1770246117,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nFWN3Z01S7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01952","BK1574","BK1161","BK1583"],"gpt_icon":0},{"id":"2609706311","title":"Everest Medicines schließt Lizenzvereinbarung mit Micot zur Kommerzialisierung von MT1013 in China und Asien","url":"https://stock-news.laohu8.com/highlight/detail?id=2609706311","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609706311?lang=en_us&edition=fundamental","pubTime":"2026-02-05 07:01","pubTimestamp":1770246102,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL3HXjjs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","BK0143","BK1574","BK0072","BK0121","BK0122","BK0214","BK0188","000988","BK1161","BK0076","BK0073","BK1583","BK0028"],"gpt_icon":0},{"id":"2609311772","title":"Everest Medicines Ltd - Agreement With Micot to Commercialize Mt1013 in Greater China and Other Asian Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2609311772","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609311772?lang=en_us&edition=fundamental","pubTime":"2026-02-05 07:01","pubTimestamp":1770246095,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nFWN3Z015K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01952","BK1583","BK1574"],"gpt_icon":0},{"id":"1143162492","title":"Everest Medicines (1952) Announces Extraordinary General Meeting on 24 February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1143162492","media":"Bulletin Express","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143162492?lang=en_us&edition=fundamental","pubTime":"2026-02-03 17:07","pubTimestamp":1770109654,"startTime":"0","endTime":"0","summary":"Everest Medicines Limited (Stock Code: 1952) has released a notice of an extraordinary general meeting (EGM) to be held on Tuesday, 24 February 2026 at 10:00 a.m. via an online platform. Shareholders...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"gpt_icon":0},{"id":"1186205253","title":"Everest Medicines (1952) Announces Continuing Connected Transactions, Proposed Connected-Person Award, and 2026 Share Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1186205253","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186205253?lang=en_us&edition=fundamental","pubTime":"2026-02-03 17:06","pubTimestamp":1770109569,"startTime":"0","endTime":"0","summary":"Everest Medicines (1952) has released a circular detailing multiple proposals for shareholders’ consideration. The company scheduled an Extraordinary General Meeting (EGM) on 24 February 2026 at...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":-0.1194},{"period":"1month","weight":-0.0931},{"period":"3month","weight":-0.2477},{"period":"6month","weight":-0.4381},{"period":"1year","weight":-0.3122},{"period":"ytd","weight":-0.0784}],"compareEarnings":[{"period":"1week","weight":-0.0566},{"period":"1month","weight":-0.057},{"period":"3month","weight":-0.0265},{"period":"6month","weight":-0.0066},{"period":"1year","weight":0.1006},{"period":"ytd","weight":-0.0149}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Everest Medicines Ltd is a biopharmaceutical company primarily engaged in the discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines. The Company has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Company’s products portfolio includes Nefecon (TARPEYO) using in the renal therapeutic area, XERAVA (eravacycline) using in the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant isolates and other products. The Company conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01035},{"month":2,"riseRate":0.333333,"avgChangeRate":0.039331},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.01315},{"month":4,"riseRate":0.2,"avgChangeRate":-0.095155},{"month":5,"riseRate":0.4,"avgChangeRate":-0.02945},{"month":6,"riseRate":0.8,"avgChangeRate":0.307082},{"month":7,"riseRate":0.2,"avgChangeRate":-0.114966},{"month":8,"riseRate":0.2,"avgChangeRate":-0.112869},{"month":9,"riseRate":0.6,"avgChangeRate":0.046163},{"month":10,"riseRate":0.4,"avgChangeRate":-0.024036},{"month":11,"riseRate":0.5,"avgChangeRate":0.086142},{"month":12,"riseRate":0.666667,"avgChangeRate":0.131823}],"exchange":"SEHK","name":"EVEREST MED","nameEN":"EVEREST MED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"EVEREST MED(01952),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest EVEREST MED(01952) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"EVEREST MED,01952,EVEREST MED股票,EVEREST MED股票老虎,EVEREST MED股票老虎国际,EVEREST MED行情,EVEREST MED股票行情,EVEREST MED股价,EVEREST MED股市,EVEREST MED股票价格,EVEREST MED股票交易,EVEREST MED股票购买,EVEREST MED股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"EVEREST MED(01952),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest EVEREST MED(01952) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}